Acumen Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $230.7M
- Price
- $3.16
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.04%
- Volume
- 716.0K
About
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Quick stats
Shares outstanding72.3M
Computed float37.4M
Float / shares51.7%
Cash runway (months)11.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001576885
Websitehttps://acumenpharm.com
AI Summary
AI-generated1/15
minorneutralearnings
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals reported a Q2 net loss of $32.7 million, or ($0.45) per share, narrowing from a $41.0 million loss in the prior-year quarter as R&D expenses decreased to $27.8 million.
The company holds $110.2 million in cash and equivalents, which management expects will support clinical and operational activities into early 2027.
Acumen reiterated that topline results from the Phase 2 ALTITUDE-AD study of sabirnetug are anticipated in late 2026, while the EBD program targets a mid-2027 IND filing.
Red flags
- Cash runway into early 2027 leaves minimal buffer following the late 2026 Phase 2 data readout.